Effects of Liquorice Juice on the Pharmacokinetics of Esomeprazole
Main Article Content
Keywords
esomeprazole; proton pump inhibitors; licorice; pharmacokinetics; drug interactions
Abstract
The HPLC-MS technique was tested and verified in this work to quantify esomeprazole in rat plasma samples. A rat investigation demonstrated that co-administration of a single dosage of liquorice juice had no effect on the pharmacokinetic characteristics of esomeprazole, however successive doses of liquorice juice raised the t1/2 and area under the curve of esomeprazole. After introducing liquorice juice into the stomach, the pharmacokinetics of esomeprazole was determined simultaneously by HPLC-MS. The absorption of esomeprazole was rapid; esomeprazole was detected in plasma from the first blood sampling time, and the peak plasma concentration for the esomeprazole-treated group with multiple doses of liquorice was reached one hour after oral administration. At the same time, peak plasma concentration was reached 30 min after oral administration for the esomeprazole-treated group
with a single dose of liquorice or distilled water. The plasma concentrations of esomeprazole in the esomeprazole-treated group with single-dose liquorice were comparable to those with single-dose distilled water. The plasma concentrations of esomeprazole were higher in the esomeprazole treated group with multiple doses of liquorice than in the esomeprazole treated group with single-dose
distilled water, resulting in a significantly higher AUC, 2.5 times, in the esomeprazole treated group with multiple doses of liquorice. This could be due to decreased metabolism of esomeprazole by multiple doses of liquorice. Since esomeprazole is metabolized in the liver mainly by CYP2C19 and liquorice is a moderate inhibitor of CYP2C19 in humans there was an inhibition of CYP2C19 at
multiple doses of liquorice. The inhibited metabolism of esomeprazole by liquorice resulted in asignificantly higher Cmax, 1.5 times, and a significantly longer terminal half-life, 1.45 times, than in the control group. Therefore, multiple administration of liquorice could increase the esomeprazole effect since a single dose did not affect esomeprazole metabolism.
References
doi:10.1517/14656566.4.2.253.
2. PB, K.-P.; HK, L.; WT, S. Esomeprazole for Acid Peptic Disorders. Ann Pharmacother 2002, 36, 655–663, doi:10.1345/APH.1A104.
3. M, T.; S, V.; V, S.; C, S. Clinical Pharmacology and Safety Profile of Esomeprazole, the First Enantiomerically Pure Proton Pump Inhibitor.
Dig Liver Dis 2001, 33, 600–606, doi:10.1016/S1590-8658(01)80115-8.
4. M, T.; AL, K.; YJ, Z.; L, L.; BP, L.; TS, W.; YY, D. Meta-Analysis of the Effectiveness of Esomeprazole in Gastroesophageal Reflux
Disease and Helicobacter Pylori Infection. J Clin Pharm Ther 2015, 40, 368–375, doi:10.1111/JCPT.12277.
5. LJ, S.; CJ, D.; G, M.; M, S. Esomeprazole: A Review of Its Use in the Management of AcidRelated Disorders. Drugs 2002, 62, 1503–1538,
doi:10.2165/00003495-200262100-00006.
6. Sugimoto, M.; Furuta, T. Efficacy of Esomeprazole in Treating Acid-Related Diseases in Japanese Populations. Clin Exp Gastroenterol
2012, 5, 49–59, doi:10.2147/CEG.S23926.
7. Jain, D.K.; Jain, N.; Charde, R.; Jain, N. The RPHPLC Method for Simultaneous Estimation of Esomeprazole and Naproxen in Binary
Combination. Pharm Methods 2011, 2, 167,doi:10.4103/2229-4708.90356.
8. Kendall, M.J. Review Article: Esomeprazole − the First Proton Pump Inhibitor to Be Developed as an Isomer. Aliment Pharmacol Ther 2003, 17,1–4, doi:10.1046/J.1365-2036.17.S1.1.X.
9. T, L.; L, R.; A, K.; A, J.; T, A.; G, H.; J, H.; K, R.Esomeprazole Provides Improved Acid Control vs. Omeprazole In Patients with Symptoms of
Gastro-Oesophageal Reflux Disease. Aliment Pharmacol Ther 2000, 14, 861–867, doi:10.1046/J.1365-2036.2000.00813.X.
10. Al-Qerem, W.; Jarrar, Y.B.; Al-Sheikh, I.; Elmaadani, A. The Prevalence of Drug-Drug Interactions and Polypharmacy among Elderly
Patients in Jordan. Biomedical Research (India) 2018, 29, 2561–2569, doi:10.4066/biomedicalresearch.29-18-618.
11. Andersson, T.; Hassan-Alin, M.; Hasselgren, G.; Röhss, K. Drug Interaction Studies with Esomeprazole, the (S)-Isomer of Omeprazole.
Clin Pharmacokinet 2001, 40, 523–537.
12. Andersson, T.; Hassan-Alin, M.; Hasselgren, G.;Röhss, K. Drug Interaction Studies with Esomeprazole, the (S)-Isomer of Omeprazole.
Clinical Pharmacokinetics 2001 40:7 2012, 40, 523–537, doi:10.2165/00003088-200140070-00004.
13. Wael A Abu Dayyih; Mallah, E.M.; Israa H AlAni2israa H Al-Ani2; Tawfiq A Arafat Liquorice Beverage Effect On The Pharmacokinetic
Parameters Of Atorvastatin, Simvastatin, And Lovastatin By Liquid Chromatograph Available online:
https://scholar.googleusercontent.com/scholar?q=cache:A3VmfdMTHKgJ:scholar.google.com/+liquorice+juice+interaction&hl=en&as_sdt=0,5
(accessed on 8 October 2021).
14. Al-Khalil, S. A Survey of Plants Used in Jordanian Traditional Medicine. Pharm Biol 1995, 33, 317–323, doi:10.3109/13880209509065385.15. Batiha, G.E.-S.; Beshbishy, A.M.; El-Mleeh, A.; Abdel-Daim, M.M.; Devkota, H.P. Traditional Uses, Bioactive Chemical Constituents, and
Pharmacological and Toxicological Activities of Glycyrrhiza Glabra L. (Fabaceae). Biomolecules 2020, 10, doi:10.3390/BIOM10030352.
16. Parvaiz, M.; Hussain, K.; Khalid, S.; Hussnain, N.; Iram, N.; Hussain, Z.; Ali, M.A. A Review: Medicinal Importance of Glycyrrhiza Glabra L.
(Fabaceae Family). Global Journal of Pharmacology 2014, 8, 8–13, doi:10.5829/IDOSI.GJP.2014.8.1.81179.
17. Pastorino, G.; Cornara, L.; Soares, S.; Rodrigues, F.; Oliveira, M.B.P.P. Liquorice (Glycyrrhiza Glabra): A Phytochemical and Pharmacological
Review. Phytotherapy Research 2018, 32, 2323– 2339, doi:10.1002/PTR.6178.
18. Thakur, A.K.; Raj, P. Pharmacological Perspective of Glycyrrhiza Glabra Linn.: A MiniReview. J Anal Pharm Res 2017, Volume 5,
doi:10.15406/JAPLR.2017.05.00156.
19. J, H.; O, U.; MJ, S. Effects of Low-Dose Liquorice Alone or in Combination with Hydrochlorothiazide on the Plasma Potassium in
Healthy Volunteers. Blood Press 2009, 18, 192–195, doi:10.1080/08037050903072515.
20. YC, H.; SP, L.; PD, C. Liquorice Reduced Cyclosporine Bioavailability by Activating PGlycoprotein and CYP 3A. Food Chem 2012,
135, 2307–2312,doi:10.1016/J.FOODCHEM.2012.07.061.
21. Swamy, M.Y. New Spectrophotometric Determination Of Esomeprazole In Bulk And Pharmaceutical Dosage Form Using Wool Fast
Blue. Journal of Drug Delivery and Therapeutics 2018, 8, 320–322, doi:10.22270/JDDT.V8I4.1802.
22. Gosavi, S.; Bhavar, G.; Sutariya, B.; Sinkar, N.;Sonawane, R. Spectrophotometric Determination of Esomeprazole in Bulk and Tablet Formulation.Analytical Chemistry: An Indian Journal 2008, 7,642–644.
23. Jain, V.; Shah, V.K.; Jain, P.K. HPLC MethodDevelopment and Validation for the Estimation of Esomeprazole in Bulk and Pharmaceutical
Dosage Form. Journal of Drug Delivery andTherapeutics 2019, 9, 292–295, doi:10.22270/JDDT.V9I4.3046.
24. Önal, A.; Öztunç, A. Development andValidation of High Performance Liquid Chromatographic Method for the Determination
of Esomeprazole in Tablets. J Food Drug Anal2020, 14, 8, doi:10.38212/2224-6614.2503.
25. Chunduri, R.H.B.; Dannana, G.S. Developmentand Validation of a High Throughput UPLC–MS/MS Method for Simultaneous Quantification
of Esomeprazole, Rabeprazole and Levosulpiridein Human Plasma. J Pharm Anal 2016, 6, 190–198, doi:10.1016/J.JPHA.2016.01.001.
26. Hultman, I.; Stenhoff, H.; Liljeblad, M.Determination of Esomeprazole and Its TwoMain Metabolites in Human, Rat and Dog Plasma
by Liquid Chromatography with Tandem MassSpectrometry. Journal of Chromatography B2007, 848, 317–322,
doi:10.1016/J.JCHROMB.2006.10.074.
27. Liu, R.; Li, P.; Xiao, J.; Yin, Y.; Sun, Z.; Bi, K.;Li, Q. A Fast, Sensitive, and High ThroughputMethod for the Determination of Esomeprazole in
Dog Plasma by UHPLC–MS/MS: Application toFormulation Development of the CompoundPreparation of Esomeprazole. Journal of
Chromatography B 2017, 1068–1069, 352–357,doi:10.1016/J.JCHROMB.2017.11.002.
28. Rossi, A.; Castrati, L.; Colombo, P.; Flammini,L.; Barocelli, E.; Bettini, R.; Elviri, L.Development and Validation of a DESIHRMS/MS Method for the Fast Profiling ofEsomeprazole and Its Metabolites in Rat Plasma:A Pharmacokinetic Study. Drug Test Anal 2016,8, 208–213, doi:10.1002/DTA.1805.
29. Israa H. Al-ani, B.A.O. andT.A.M.S.E.M.R.A.W.A.D.F.D.E. Determinationof Carbamazepine in Rat Plasma in the Presenceof Licorice Juice by Using HPLC and ItsPharmacokinetic Applications. J Chem PharmRes 2015, 7, 116–126.
30. Singh, T.P.; Chauhan, G.; Agrawal, R.K.;Mendiratta, S.K. In Vitro Study on Antimicrobial,Antioxidant, FT-IR and GC–MS/MS Analysis of
Piper Betle L. Leaves Extracts. Journal of FoodMeasurement and Characterization 2019, 13,466–475, doi:10.1007/s11694-018-9960-8.
31. Davies, N.M.; Anderson, K.E. Clinical Pharmacokinetics of Naproxen. Clin Pharmacokinet 1997, 32, 268–293.
32. Dean, L. Esomeprazole Therapy and CYP2C19Genotype; National Center for BiotechnologyInformation (US), 2012;
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.